Stereotaxis, Inc. STXS

New digital technologies, including Synchrony and SynX, will be featured at HRXStereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its portfolio of digital and robotic technologies will be featured at Heart Rhythm Society’s HRX conference, taking place September 18-20, 2026, in Atlanta, Georgi

University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in JulyOver 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globallyRobotics enabled successful treatment of patients with multiple previously failed ablation proceduresUniversity of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8th ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ste

Moby summary of Stereotaxis, Inc.'s Q2 2026 earnings call

Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints. Revenue declined from the prior-year quarter be

Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentiallyFirst GenesisX robotic system purchase by US hospital to be installed this fallMultiple Synchrony digital operating room systems sold and installed following FDA clearance in AprilCompleted previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer an

Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AUSTIN, Texas, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Myriam Curet, M.D., to the Board as an independent director, effective July 30, 2026. “We are thrilled Myriam will be joining the Mobia Medical Board of Directors,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “Her decade

ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter

First Robotic Magnetic Navigation system installed in HungaryUniversity of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the

Assessing Stereotaxis Shelf Registrations and Capital Flexibility Stereotaxis (STXS) has filed multiple shelf registrations that would allow the company to offer up to 128,317,934 common shares, totaling roughly US$205.3 million, putting potential capital raising and dilution firmly on investors radar. See our latest analysis for Stereotaxis. Stereotaxis shares closed at US$1.55 after a sharp 1 day share price decline of 6.06%, extending a year to date share price fall of 33.19% and a 1 year...